Company Overview and News

13
Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer

2018-09-17 marketwatch - 1
Cellectar Biosciences Inc. CLRB, -2.23% said Monday it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for a treatment for a rare kind of cancer in children called osteosarcoma. The treatment, CLR 131, is the company's lead Phospholipid Drug Conjugate(TM) (PDC) product candidate, which delivers radiation directly to cells. "CLR 131 has demonstrated promise as an anticancer agent in preclinical and clinical settings, and we are working now to establish its impact on various rare and deadly pediatric cancers," said John Friend, M.
CLRB CLRBZ CLRBW

13
Cellectar Biosciences stock surges 23% premarket

2018-09-17 marketwatch - 1
Cellectar Biosciences Inc. said Monday it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for a treatment for a rare kind of cancer in children called osteosarcoma. The treatment, CLR 131, is the company's lead Phospholipid Drug Conjugate(TM) (PDC) product candidate, which delivers radiation directly to cells. "CLR 131 has demonstrated promise as an anticancer agent in preclinical and clinical settings, and we are working now to establish its impact on various rare and deadly pediatric cancers," said John Friend, M.
CLRB CLRBZ CLRBW

12
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

2018-09-17 globenewswire
MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131 for the treatment of osteosarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

14
Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-29 globenewswire - 2
MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.
CLRB CLRBZ CLRBW

12
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

2018-08-20 globenewswire
Positive Results from Cohort 5 of Phase 1b Trial Company Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose
CLRB CLRBZ CLRBW

41
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

2018-08-14 seekingalpha - 1
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
MBIO REDIF APOP RDHL ACER ARQL MGTX STML CLRBZ CLRBW MCUJF ABBV CLRB APOPW ALNY ABBV VNRX

13
Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

2018-08-13 globenewswire - 1
MADISON, Wis., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of Ewing’s sarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

29
Your Daily Pharma Scoop: Theravance Positive, Denali Encouraging, Redhill Clarifies Data

2018-08-03 seekingalpha - 1
Theravance Biopharma (TBPH) reported positive data of a four-week data from a Phase 2 clinical trial of TD-9855. The candidate is an once-daily norepinephrine and serotonin reuptake inhibitor. It is indicated in patients with rare disorder called symptomatic neurogenic orthostatic hypotension (‘nOH). A person with the disorder is characterized by low pressure when she stands up.
REDIF CERC BLRX RDHL TROV CLRBZ CLRBW DNLI RXII TBPH CLRB NMRD

14
Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering 

2018-07-27 globenewswire - 2
MADISON, Wis., July 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB) (“Cellectar” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of $14.4 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.
LTS-A CLRB LTS CLRBZ CLRBW

83
Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

2018-07-20 seekingalpha - 1
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement.
MBRX ADAP ENZ AZN KPTI OVID CTIC CTI LLY CLRBZ SNY CLRBW CBIO IMMU JNJ NVS CLRB PFE ATOS

39
Your Daily Pharma Scoop: Voyager Advances, Roche Succeeds, Eisai Positive

2018-07-19 seekingalpha - 2
Voyager advancing gene therapy for Parkinson's, Phase 2 data may be sufficient for U.S. marketing application
SGEN AST RCUS ACIU BAX CLRBZ CLRBW VYGR PULM TRPX CLRB AXON

12
Cellectar Biosciences Strong Preliminary Data For Rare Cancer Treatment Is Encouraging

2018-07-18 seekingalpha
Preliminary results for a phase 2 study using CLR 131 to treat one patient with Waldenstrom macroglobulinemia showed a 94% reduction in tumor burden with only 2 doses.
CLRB CLRBZ CLRBW

13
Cellectar Biosciences shares surge 60% on results for one cancer patient in mid-stage trial

2018-07-17 marketwatch - 1
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CLRB CLRBZ CLRBW

13
Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study

2018-07-17 globenewswire - 1
MADISON, Wis., July 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that a patient in the lymphoplasmacytic lymphoma (LPL) arm with advanced Waldenstrom macroglobulinemia, enrolled in the CLR 131 Phase 2 trial, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses.
CLRB CLRBZ CLRBW

12
ECA2018-118 - Reverse Split and CUSIP Number Change for Cellectar Biosciences, Inc. (CLRB)

2018-07-16 nasdaqtrader
Cellectar Biosciences, Inc. (CLRB) will effect a one-for-ten (1-10) reverse split of its common stock. The reverse stock split will become effective on Tuesday, July 17, 2018. In conjunction with the reverse split, the CUSIP number will change to 15117F500.
CLRB CLRBZ CLRBW

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 15117F120